Abstract:Arsenic compounds, including arsenic trioxide (As2O3) and arsenic sulfide (As4S4), have recently been shown to be effective in the treatment of acute promyelocytic leukemia (APL). In vitro, As2O3 exerts a dosedependent dual effect: it triggers apoptosis at relatively high concentrations (0.5 to 2.0 μmol/L) and induces partial differentiation at low concentrations (0.1 to 0.5 μmmol/L). The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the retinoic acid signaling is required for APL cell differentiation. As2O3 over a wide range of concentrations (0.1 to 2.0 μmol/L) induces degradation of PML-RARα as well as the wild-type PML and enhances the acetylation of histone, a process important for the transcriptional activation of genes. In vivo, As2O3 induces a high complete remission (CR) rate in patients with both primary and relapsed APL (around 85% to 90%). Side effects, such as skin reaction, gastrointestinal symptoms, electrocardiographic (EKG) changes, neuropathy, and liver dysfunction, are mild to moderate in relapsed patients, and severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as postremission therapy has yielded better survival than treatment with As2O3 alone. This is in line with the observation that remission induction with As2O3 is not sufficient in most cases to obtain a molecular remission as judged by reverse-transcriptase polymerase chain reaction for PML-RARα fusion transcripts. The in vivo effect of As2O3 seems to be related to the expression of APL-specific PML-RARα oncoprotein, and a synergistic effect between As2O3 and ATRA has been shown in the APL mouse model. Besides As2O3, other arsenic compounds such as As4S4 also show a therapeutic effect in APL. Because the toxic effects of arsenic treatment in primary APL need to be investigated further, we propose use of ATRA as a first-line drug for remission induction in primary APL, whereas As2O3 can be incorporated into multidrug postremission therapy or used as rescue for relapsed APL patients.

Phenylarsine Oxide Can Induce Degradation of PLZF-RARα Variant Fusion Protein of Acute Promyelocytic Leukemia

Phenylarsine Oxide Can Induce The Arsenite-Resistance Mutant Pml Protein Solubility Changes

Research Advance on the Role of Ubiquitin Proteasome Pathway In Acute Promyelocytic Leukemia——Rewiew

Arsenic-induced PML Targeting Onto Nuclear Bodies: Implications for the Treatment of Acute Promyelocytic Leukemia

Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission

Phenylarsine oxide (PAO) induces apoptosis in HepG2 cells via ROS-mediated mitochondria and ER-stress dependent signaling pathways.

Arsenic trioxide, a therapeutic agent for APL.

Curing APL through PML/RARA degradation by As2O3.

Combination of arsenic trioxide and chemotherapy in the treatment of PLZF/RARα positive acute promyelocytic leukemia patient: a case report and literature review

Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

Data from Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function

Irreversibility of Arsenic Trioxide Induced PML/RARα Fusion Protein Solubility Changes.

Treatment of Acute Promyelocytic Leukemia with Arsenic Compounds: in Vitro and in Vivo Studies

Arsenic Trioxide and P97 Inhibitor Synergize Against Acute Myeloid Leukemia by Targeting Nascent Polypeptides and Activating the ZAKα-JNK Pathway

PML-RARα Stabilized by Zinc in Human Acute Promyelocytic Leukemia NB4 Cells

Hyperthermia Selectively Destabilizes Fusion Oncoproteins

Arsenic induced epigenetic changes and relevance to treatment of acute promyelocytic leukemia and beyond

[Involvement of PML Proteins in Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide].

Arsenic Degrades PML or PML–RARα Through a SUMO-triggered RNF4/ubiquitin-mediated Pathway

Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia